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Does Response to Glaucoma Therapy in One Eye Predict Response in the Fellow Eye?
Omar R. Chaudhary, Ron A. Adelman, and M. Bruce Shields. Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT.
Purpose: To study if the intraocular pressure (IOP) change observed after starting a
glaucoma medication in one eye is predictive of the change in IOP observed in the fellow
eye once the same medication is used in both eyes.
Methods: In a retrospective study, 55 patients with glaucoma underwent monocular drug
trials with various medications before the drug was added to the second eye. The change
in IOP of the first treated eye during monocular therapy was compared with the IOP
change of the second eye during binocular therapy. Relative changes in IOP of each eye
were calculated by subtracting the change in IOP of the fellow eye from the treated eye.
Results: The IOP of the first eye decreased 5.8 ± 6.1 mmHg (mean ± standard deviation)
during monocular therapy and the IOP of the second eye decreased 3.4 ± 5.7 mmHg
during binocular therapy. The absolute IOP changes in the first and second eyes were
poorly correlated (r = 0.095, p = 0.49). When relative changes in IOP were used, the first
eye decreased 6.3 ± 5.3 mmHg and the second eye 4.2 ± 4.5 mmHg. The relative changes
were well correlated (r = 0.404, p = 0.002). Excellent correlation was noted in the subset
of glaucoma suspect patients when using absolute IOP changes (r = 0.590, p = 0.001).
Conclusions: The data supports that the absolute response of one eye to a medication is
predictive of the future response of the fellow eye to the same medication in patients with
glaucoma suspect, but not in the overall glaucoma population. If one uses one eye as a
control when assessing the efficacy of a drug in the fellow eye, then the response of one
eye to a glaucoma medication is predictive of the response of the fellow eye.
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Introduction
Glaucoma is one of the leading causes of blindness in the world and elevated
intraocular pressure (IOP) is the only proven risk factor.1 Pharmacotherapy and surgery
form the basis of treatment as the risk of progression of visual field loss decreases 10%
for each millimeter of mercury reduction in IOP.2 Other factors may also be at play as
some patients develop glaucomatous damage even with normal pressures while others
live comfortably with elevated pressures without any evidence of damage. Once the
decision has been made to start pharmacotherapy, the patient is usually started on a
monocular drug trial to test the efficacy of a drug. However, recent evidence has led
some researchers to question the validity of the monocular drug trial and advocate for
fundamentally altering the treatment strategy.3 This thesis will examine the latest
evidence on the subject and will attempt to answer some of the questions regarding the
basis of the monocular drug trial.
Before we look at the monocular drug trial, let us first examine the factors
influencing intraocular pressure. Roughly, the IOP is dependent upon the production of
aqueous humor versus the outflow through the trabecular meshwork. Elevations in IOP
are often the result of impedance in the outflow tract as there is not a known autoregulatory mechanism to maintain normal pressures. Intraocular pressure in each eye is
not constant, but instead varies throughout the day because of variables that cause both
short and long-term fluctuations in IOP. Factors influencing short-term changes in IOP
include breath holding and straining. The intake of food and water causing a change
blood osmolarity has also been proposed as a mechanism for short-term changes in IOP.4
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Long-term variations of IOP have been well studied. Intraocular pressure varies
in a 24 hour pattern, commonly referred to as each eye’s “spontaneous diurnal variation.”
These variations are described as spontaneous because of the high variability and
unpredictability of pattern noted. Diurnal variations in IOP were first observed by SidlerHuguenin in 1898 when he found the IOPs of 10 patients with glaucoma were highest at
night before sleeping and within an hour of awaking in the morning.5 These seemingly
rhythmic variations in IOP led researchers to look for correlations with systemic
processes. Weitzman et al. pointed out a correlation between the plasma cortisol level
and IOP.6 Vascular tone changes affecting aqueous production and outflow have been
postulated to influence rhythmic changes in IOP.7, 8 Despite many hypotheses that have
been proposed for the basis of the pressure cycle, further research is required to fully
explain the cause for the diurnal variations.
Spontaneous IOP changes can frequently be quite large. In a study by Drance, 404
eyes of patients without ocular disease had a mean IOP fluctuation of 3.7 mmHg over 24
hours.9 Another study by de Venecia and Davis found a similar diurnal IOP fluctuation of
4.9 mmHg in healthy individuals in a single day.10 Glaucomatous individuals, on the
other hand, have a magnitude of diurnal variation of more than double compared to
healthy patients. Katavisto found the variation to be 11.1 mmHg in individuals with
primary open angle glaucoma (POAG).5 A more recent study by Asrani et al. found that
the diurnal variation is approximately 10 mmHg.11 These variations present a problem for
ophthalmologists due to their large magnitude. One can not know if an individual’s IOP
is normal or abnormal based on a single measurement because an elevated reading could
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be attributed to a fluctuation of the diurnal cycle or actually be pathologically elevated
requiring treatment.
Researchers have attempted to characterize the diurnal pattern. Katavisto found
the peak of the diurnal cycle most commonly occurred at 6 a.m. in treatment naïve
patients and 8 a.m. in previously treated patients.5 This corresponds nicely with
previously discussed findings relating IOP with cortisol level. Recently, Zeimer stated
that diurnal rhythms fit into 4 common patterns: 1) a 24 hour cycle with an IOP peak in
the morning; 2) a 24 hour cycle with an IOP peak in the afternoon; 3) “flat” curves
without significant pressure variation; and 4) “erratic” curves that do not follow a daily
pattern.1 Wilensky et al. found that most patients had rhythmic diurnal variations in IOP
with pressure peaks in the morning.12 Only 22% of patients with ocular hypertension and
16% of patients with POAG had an erratic diurnal rhythm. It is important to learn about
the pattern of variation because as we will see, there are significant implications
regarding treatment and interpretation of disease progression. One of the most intimately
involved consequences relates to the monocular drug trial.

What is the monocular drug trial?
Since spontaneous fluctuations of intraocular pressure in patients are substantial,
it is important for ophthalmologists to differentiate spontaneous changes in IOP from
effects of pharmacotherapy.

For this reason, it has become standard practice for

ophthalmologists to institute a monocular trial of a glaucoma medication in order to
determine if a drug is efficacious.13 First, baseline IOPs of both eyes are determined
before any medications are administered. The patient is instructed to take a glaucoma
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medication in one eye, usually the eye with higher pressure.14 After a period of time
thought to be enough for the medication to take effect (usually 1 – 2 months), the patient
is seen again in the clinic to determine if the drug was successful in reducing the IOP in
the treated eye. If the clinician decides that the medication is efficacious, the patient is
instructed to start taking the drug binocularly.

If the drug is not successful, the

medication is discontinued and the monocular trial is repeated with another drug.
Since spontaneous changes in IOP are thought to occur equally in both eyes, the
untreated eye acts as a control for the treated eye during the monocular trial. Changes in
IOP of the untreated eye are presumably due only to spontaneous effects while changes in
the treated eye are from both spontaneous and therapeutic effects. If the change in IOP in
the untreated eye is subtracted from the change in the IOP of the treated eye, one can
eliminate the spontaneous variations and isolate for the therapeutic effects of the
medication.
As an example, let us take a patient whose left and right eye IOPs were 24 mmHg
prior to the initiation of the drug trial in the left eye. If at the second clinic visit, the IOP
of the left eye was 16 mmHg while the IOP of the right eye was 22 mmHg, then
spontaneous changes in IOP theoretically contributed a decrease of 2 mmHg (24 - 22 = 2)
while the therapeutic effect of the medication was a decrease of 6 mmHg (24 – 16 – 2 =
6). The medication would be determined to be efficacious based on these results and
therapy would be instituted binocularly.
However, interpreting the trial can easily become more complicated. Let us take
another patient whose initial IOPs were 24 mmHg in both eyes before treatment is
initiated in the left eye. However in this patient, at the second clinic visit the left eye’s
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IOP is 26 while the right eye’s IOP is 32. Using the same calculations as before,
spontaneous changes in IOP would account for an increase of 8 mmHg in both eyes over
this time period and the therapeutic effect of the medication would be a decrease in IOP
of 6 mmHg in the left eye. In this situation, it is uncertain whether or not this medication
would be viewed as a success. The IOP decrease calculated to be secondary to the
medication is significant; however with an absolute increase in IOP of both eyes, an
ophthalmologist would be hesitant to deem this drug as efficacious since the overall goal
is to achieve a decrease in IOP. In clinical practice at some institutions, the medication in
this example might still be deemed a successful trial. However, other researchers have
treated the quandary presented both ways.15
The debate over the monocular drug trial has centered on the trial’s two main
assumptions. First, can one eye serve as a control for the fellow eye during the monocular
drug trial? Second, will the response to therapy in one eye will be matched by a similar
response in the fellow eye, i.e. if a medication is successful in reducing the IOP in the
first eye, will it also decrease the IOP in the second eye in a similar way? We will now
examine these assumptions in detail.

Can one eye serve as a control for the fellow eye during the monocular drug trial?
Since spontaneous diurnal variations of IOP in the eyes can often be quite large,
this question is particularly important to answer. Theoretically, the treated eye during the
monocular drug trial should be affected equally by the variables influencing IOP as the
fellow eye except for the therapeutic effects of the drug. If one eye can serve as the
control for the fellow eye, the therapeutic effects of a medication can be easily
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differentiated from the natural diurnal spontaneous changes that occur by subtracting out
the spontaneous change in IOP from both eyes. If not, the large spontaneous fluctuations
in IOP can dwarf any effects from pharmacotherapy.
Two major questions have been raised when addressing this assumption. First,
when a topical glaucoma drug is added to one eye, is there any effect of the drug in the
fellow untreated eye? Secondly, are the spontaneous diurnal variations between the left
and right eye symmetric enough to allow one eye to serve as a true control for the other?
The idea that a drug applied to one eye can cause a change in IOP of the fellow
eye is known as the “crossover effect”. Zimmerman and Kaufman first came across the
effect

when they studied

the responses of 30 glaucoma patients to topical beta

adrenergic antagonists.16 They noted a significant IOP decrease in the untreated eye 5
hours after the monocular administration of 0.5% timolol maleate. They attributed this
crossover effect to possibly “rubbing of the eyes after application of treatment, systemic
absorption, or a centrally mediated effect.” Since this time, studies have clarified that
topical beta blockers are absorbed systemically, possibly through the nasolacrimal
mucosa and travel via the bloodstream to cause effects in the contralateral eye.17,
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Others have suggested a centrally mediated effect on IOP.19
Piltz et al. performed an extensive analysis of 817 patients receiving topical beta
adrenergic antagonists during the Ocular Hypertensive Treatment Study.20 They found
the mean IOP of the treated eye dropped 5.9 mmHg while the fellow untreated eye
decreased 1.5 mmHg. Both of these values were statistically significant when compared
to the control group receiving placebo and this effect was noted among both selective and
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non-selective beta blockers. Others have shown similar, but less, crossover effect in
healthy individuals.21
Topical prostaglandin medications are metabolized quicker and have less
systemic effects compared to beta blockers. Alm and Stjernschantz found that the blood
pressure in patients given topical timolol was lower than patients given topical
latanoprost.22 The implication is perhaps there is less of a crossover effect in patients
given prostaglandin analogs than with beta adrenergic antagonists. However, no
confirmatory studies have been performed. This is one of the hypotheses that will be
addressed in this thesis.
Any crossover effect would result in the underestimation of the therapeutic effect
in the monocular drug trial since the drug would have some efficacy in both eyes. In
some cases, medications would incorrectly be deemed ineffective when not much relative
improvement is noted. This is one of the limitations of the monocular drug trial and must
be taken into account when clinicians are evaluating whether a drug is efficacious.
The second question of whether the IOP of fellow eyes vary symmetrically is
more complex. In a healthy individual, the intraocular pressures in the left and right eye
are often assumed to be almost equal. In fact, Lee et al. have found that asymmetry in the
IOPs of the left and right eye is a useful sign in diagnosing primary open angle glaucoma
in patients without elevated intraocular pressures.23
However, even in healthy patients the intraocular pressures in the left and right
eye are not always equal. Liu et al. measured the IOP of 91 healthy individuals every 2
hours for 24 hours in a sleep laboratory.24 They compared the IOP of the left and right
eye and tried to determine if the IOPs were correlated at a single measurement. The
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coefficient of determination (r2) varied from .311 to .741 during different times of the
day. In other words, only 31% to 74% of the fluctuation of IOP in one eye at a single
measurement can be explained by the IOP of the fellow eye. Liu et al. further found that
there was a significant difference in the mean IOP of the left and right eye over 24 hours.
However, the authors attributed this to possibly effects from repeated tonometry, order of
measurement, or the predominance of right-handedness of patients rather than to
represent a fundamental difference in the IOPs of the fellow eyes.
In a similar study by Sit et al., 41 subjects with primary open angle glaucoma had
their IOPs measured in a sleep lab over 24 hours.25 They found the coefficient of
determination to be .416 to .536 for left and right eye IOP pairs which represents
moderate correlation. These two studies illustrate that at a single IOP measurement (for
example, during a clinic visit), the IOP of the left and right eyes are frequently dissimilar
in both healthy and glaucomatous patients.
While the IOPs of the left and right eye are only moderately correlated at a single
measurement, one eye can still serve as a control for the fellow eye if the IOPs fluctuate
symmetrically over time. Realini et al. addressed this question in a study published in
2002 when they examined if IOP fluctuations in the left and right eye were symmetric
across two consecutive visits.26 They defined the change in IOPs of a patient to be
symmetric if the change in IOP of the left eye was less than 3 mmHg different than the
change in IOP of the right eye. They found that 50% of healthy individuals and 63% of
glaucomatous patients had at least one visit where there was an asymmetric change. In
total, 13.7% of visits of healthy individuals and 16.3% of visits of glaucomatous patients
had asymmetric changes in IOP from the previous visit. There was not a statistically
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significant difference in the frequency of asymmetric visits between the two groups.
However, the frequency that asymmetric IOP changes occur is significant. Not only are
the IOPs frequently different at a single point of time, but often they seem to vary
independently.
At first glance, Realini et al.’s use of 3 mmHg as the cutoff between a symmetric
and an asymmetric change seems arbitrary. However, others have used a similar cutoff
based on upon the published variability of the equipment and technician. Sudesh et al.
found that the variability of IOP measurements on the same eye by different observers
using an applanation tonometer was 3 mmHg or less 80% of the time.27 Others have
found less than a 3 mmHg variation in repeated measurements on the same patient by the
same examiner more than 90% of the time.28, 29 A study by dos Santos et al. found that
measurements taken with Goldmann applanation tonometry had less variation than
measurements taken with Perkins hand-held applanation tonometry.30 A study by
Wittenberg found that the standard deviation of repeated pneumatonometry readings was
1.75 mmHg.31 Since a high percentage of readings usually fall within 3 mmHg, this is
usually taken as the acceptable cutoff for determining asymmetry between IOP
measurements. Any change above 3 mmHg, therefore, is considered a significant change
and not attributed to intraobserver or interobserver variability. A cut-off of 15% change
in IOP has been also used to represent a significant IOP fluctuation.26
The literature suggests that the IOP in the left and right eye are frequently not
equal and may vary independently of each other. These conclusions have been based on
finding asymmetry of IOPs in the left and right eye on a single measurement or in the
change between two consecutive measurements. The problem with drawing conclusions
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based on a single IOP reading at a point in time is that one can not be sure where this
reading lies on an individual’s IOP curve. If both eyes of an individual had the same
diurnal IOP curve but lied on different points of the curve at a certain point of time, the
two eyes would have unequal IOPs and be falsely asymmetric under the single IOP
measurement methodology. Perhaps the reason why the IOP readings in the studies
quoted above were not equal is that fellow eyes were at different points of the diurnal
curve and one eye was measured at the peak and the fellow eye at the trough. In other
words, one can not make conclusions about the symmetry of the IOPs of the left and right
eye, or even the peak or mean IOP of the diurnal curve based on a single measurement.
Others have thought a better strategy is to look for symmetry by plotting diurnal curves
by taking multiple measurements over the course of a day. These data are not usually
available since IOP is usually measured once during an office visit.
Liu et al. fit curves to the averaged 24 hour data of the left and right eye and
found significant similarities in the diurnal curves’ shape and amplitude.24 The pressure
curve acrophase (the time that the overall pressure curve is equal to the mean IOP) was
8:22 a.m. (SD = 394 min) for the right eye of a younger group of patients and 7:43 a.m.
(SD = 375 min) for the left eye. A similar finding was seen in an older group: left eye
acrophase was 7:37 a.m. (SD = 334 min) and right eye 8:19 a.m. (SD = 301 min). Of
note, large standard deviations in the range of 5 to 6 hours indicate that perhaps many
dissimilarities exist between individual diurnal pressure curves even though the overall
pressure curves are similar. Since each patient’s IOP is evaluated independently in
clinical practice, it is dubious to make conclusions based on averaged IOP data as in this
study.
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Wilensky et al. showed that this was in fact true when they looked at the type of
diurnal variation cycle that each eye follows.12 They mapped diurnal pressure curves in
176 patients with primary open angle glaucoma and 55 patients with ocular hypertension
(OHT) by measuring IOP 5 times per day over a period of 5 days. Each eye was
characterized to a type of diurnal pressure curve to which it fit best as defined previously
by Zeimer et al. (see above).1 They found that 33% of the patients with OHT and 36% of
patients with POAG had different types of pressure curves in the left and right eyes! This
was a significant difference from the control group where only 6% of the patients had
different diurnal pressure curves in the left and right eyes (p = 0.05 and p = 0.03
respectively). In fact, when diurnal pressure curves were remapped on the same eyes
months later, only 28% of eyes of OHT patients and 44% of eyes of POAG patients had
the same curve as before. So, not only do a significant number of left and right eyes
follow different diurnal curves at one point in time, but even the same eye may have a
different curve when measured at a later date. This does not support the practice of
ophthalmologists who draw conclusions about the diurnal curve by taking IOP
measurements over many successive clinical visits. This is a significant finding which
needs to be confirmed with further studies.
Sit et al. tried another method to determine if the left and right eye diurnal
pressure curves were related.25 They tried to fit the 24 hour IOP data to statistical models
to see if the IOP of one eye could be predicted based on the IOP of the fellow eye. This
drives to the heart of the monocular drug trial, because even if the diurnal curves are not
symmetric, if the IOP of one eye can be predicted by the IOP of the fellow eye, then
reasonable conclusions can be made using the IOP of just a single eye. The first model

16
they assessed was the “symmetric model” which assumed that if the IOP of the left eye
increased by 1 mmHg, the right eye’s IOP should also increase by 1 mmHg. This is the
assumption that is used in clinical practice, i.e. if the IOP of the left eye increases from 24
mmHg to 26 mmHg, the right eye should also have a 2 mmHg increase over the same
time period. Using this model, if the IOP predicted was greater than 3 mmHg different
than the actual IOP then it was considered an inaccurate prediction. In the symmetric
model, 14% (SD = 12%) of the predictions were inaccurate. This is similar to the results
reported above by Realini et al. which reported that 16.3% of glaucomatous patients’ IOP
measurements had greater than a 3 mmHg difference in IOP change between the left and
right eye.26
The second model they tried was the “best fit model” using least-squares linear
regression analysis. This method utilizes many IOP readings to create a differential
equation that approximates the relationship between the IOP of the left and right eye. If
given the IOP of one eye, one can use the equation to estimate what the IOP should be in
the fellow eye. Only 8.5% (SD = 10.6%) of the predicted measurements were greater
than 3 mmHg different than the actual IOP measurements with the best fit model which is
an improvement over the symmetric model. However, these results must be taken with a
grain of salt. The 8.5% of inaccurate predictions only reflects the quality of the model of
fitting the given data that it was based on. It is unknown whether the model can predict
future IOP values with the same accuracy. Wilensky et al. presented evidence (see
above) that showed that one can not assume the relationship between the left and right
eye is stable over time because a significant proportion of diurnal curves may have
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shifted.12 A study examining the accuracy of the best fit model in predicting future IOP
values still needs to be performed.
A problem with using multiple measurements during clinic visits to create a
diurnal pressure curve is that one can not be certain that the IOP maximum is found
unless a continuous IOP measurement device is developed and used over a 24 hour
period. In fact, the pressure peak is often missed in clinical practice. Wilensky et al.
found that in patients who had IOPs measured less than 21 mmHg and yet still had
evidence of progression of disease, more than 50% were found to have pressure spikes of
greater than 22 mmHg when their full diurnal curves were measured.32 They also found
in 50% of these patients, the IOP peak noted was either before 8 a.m. or after 5 p.m. In a
follow up study, Wilensky et al. found that 48% of all ocular hypertensive patients and
43% of all primary open angle glaucoma patients had IOP peaks outside of normal office
hours.12 In fact, in patients who develop glaucomatous damage even with pressures in the
normal range, it has been postulated that perhaps these patients did have elevated
nighttime IOP spikes that were not picked up on routine clinic measurements.11 Thus,
important pressure peak determinations may be missed when only performing routine
IOP measurements during clinic visits.
Another important value when assessing pressures is the fluctuation of IOPs over
the course of a day. One study found that the range of IOPs is more predictive of
glaucomatous damage than the mean or peak IOP.11 As a result, there has been an effort
to develop methods to minimize the daily variation of IOP. Some glaucoma medications
such as pilocarpine, carbonic anhydrase antagonists, and alpha-2 adrenergic agonists have
short durations of action and wear off before the next dose is administered which would
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result in a large range of IOP fluctuation. In contrast, medications with longer durations
of action such as prostaglandins have been shown to reduce the range of IOPs and thus,
be more effective at preventing glaucomatous damage.33
Others have looked at the effects of laser or ocular surgery on IOP. Glaucoma
procedures altering the trabecular meshwork may result in a different diurnal curve.
Agarwal et al. noted that in 40 eyes with POAG which had undergone argon laser
trabeculoplasty, the mean IOP decreased from 25.8 mmHg to 17.8 mmHg and the
average range from 7.9 mmHg to 3.2 mmHg.34 However, as with any studies looking at
the change in the range of IOPs after an intervention that lowers the mean IOP, it is
unclear what implications to draw because the range of IOPs should also decrease with a
lower mean IOP.
The purpose of first administering the drug in one eye (i.e. the monocular drug
trial) is to allow the clinician to differentiate the spontaneous variations of IOP from the
therapeutic variations by having one eye serve as a control for the fellow eye. However
as we have seen, many studies have cast doubt on this crucial assumption. A single IOP
measurement is insufficient in predicting IOP because of the significant independent
diurnal variation between eyes. Multiple measurements can be used to learn more about
diurnal variations; however it is important to map each eye’s diurnal curve instead of
finding the mean IOP because the range of IOPs also has significance. Further research is
needed to determine if the diurnal cycles of the left and right eye are symmetric and are
stable over time. If one can predict the IOP of one eye using the fellow eye’s IOP diurnal
curve, then the monocular trial can still be reliably used. This debate continues to be
unresolved and plays prominently in the discussion about the monocular drug trial.
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Is the response to the therapy in one eye matched by a similar response in the fellow eye?
In order for the monocular trial to guide therapy, a success in one eye must be
accompanied by a symmetric decrease in IOP when the drug is administered to the fellow
eye. Realini et al. tested this second assumption in their 2004 paper by measuring the
IOP response of the treated eye during the monocular drug trial versus the IOP response
of the fellow eye during binocular treatment.15 However, citing the significant
asymmetric spontaneous diurnal fluctuations in IOP discussed above, they did not use the
untreated eye as a control for the treated eye during the monocular phase, nor did they
use the originally treated eye as a control for the second eye during the binocular phase.
They instead compared absolute changes in IOP of the eyes in question. The first eye IOP
decreased 5.7 mmHg (SD = 3.8) during monocular therapy and the second eye decreased
2.8 mmHg (SD = 3.3) during binocular therapy. The changes in IOP were very poorly
correlated (r2 = 0.0174, p = 0.35). Because of evidence showing little cross-over effect in
topical prostaglandin use, the subset of the patient population who only received
prostaglandin analogs were analyzed separately. Again, little correlation was seen (r2 =
0.024, p = 0.449). Neither the type of glaucoma nor a history of surgery improved the
correlation between the change of IOP in the first eye during monocular therapy and the
second eye during binocular therapy.
The results from Realini et al. were surprising. They postulated that perhaps,
fellow eyes actually have asymmetric therapeutic responses to medication due to
asymmetries in aqueous production or outflow. A more likely explanation is that large
spontaneous changes confounded each data measurement. This study is subject to the
problems associated with using only one reading of IOP instead of mapping the entire
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diurnal curve. The measurements quite possibly could have been made at different points
on the diurnal curve (meaning differences in IOP noted were due to spontaneous changes
instead of therapeutic changes), or perhaps on different diurnal curves entirely. Inability
to control for spontaneous variation between fellow eyes is a major flaw in the study
design and is resulting from their decision to not use the fellow eye as a control.
Another limitation of Realini et al.’s results is based on that fact that in clinical
practice as well as in this trial, the eye chosen for treatment is the eye with the higher
IOP.14

The IOP must be sufficiently high for a clinician to decide to start

pharmacotherapy. A selection bias is introduced because it is more likely that the IOP at
the last measurement before therapy is initiated is closer to the peak of the diurnal curve
than at the mean. However, at the second visit when the monocular drug trial is assessed,
there is no tendency of the IOP to be a certain part of the curve and instead, the IOP
measured should be close to the mean IOP. If this is the case, not only would the
therapeutic benefit of the medication be seen at the second visit, but in general, the
pressures would be moving on average from the peak of the diurnal curve to the mean.
This phenomenon is referred to as “regression to the mean” and may be contributing to
the asymmetries in the IOP change observed by the authors. Again, it would be averted
by mapping the full diurnal curve instead of making conclusions based on a single
measurement. In fact, in Realini et al.’s study, the average change in IOP seen in the first
eye was 5.7 mmHg and 2.8 mmHg in the fellow eye which is a difference of only 2.9
mmHg. This is less than the 3 mmHg accepted standard allowed for spontaneous
variation of IOP (discussed above).30 In other words, the 2.9 mmHg difference noted
could completely be explained by regression to the mean. Realini et al. contends that this
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effect should occur equally in both eyes to balance out. The second eye’s IOP would also
have to be sufficiently high to warrant pharmacotherapy. If the second eye’s IOP is not
sufficiently high to warrant treatment, the patient would be maintained on monocular
therapy and not included in the trial. Although there are significant questions raised by
the paper, no confirmatory studies have been performed.
In light of their findings that a monocular trial of a drug did not predict fellow eye
response, Realini et al. performed a follow-up study published in 2005 where they
administered medication to both eyes at the same time.3 They compared absolute changes
in IOP before and after treatment and found extremely high correlation (r2 = 0.7, p <
0.0001). There was less than a 2 mmHg difference in IOP between the left and right eye
in 67% of patients. As a result, they conclude that the monocular drug trial fails because
of asymmetric spontaneous changes between fellow eyes and not because of asymmetric
therapeutic changes. They propose that instead of using the monocular drug trial to test
the efficacy of a medication, the drug should be started in both eyes at the same time and
each eye be assessed independently for response to the medication. However, they do not
address the conflicting results between this study and their previous study. In both
studies, they used a single IOP measurement to determine baseline and post-treatment
IOP and therefore did not account for spontaneous diurnal fluctuations. Perhaps there
were too many confounding variables in the first trial related to the different time periods
being analyzed that that did not come into play in the second trial.
There have been significant objections raised about the assumptions that form the
basis of the monocular drug trial. This has led at least one group of authors to advocate
for rejection of the practice and the adoption of initiation of binocular therapy with
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independent assessment of efficacy for each eye. However, conflicting findings have
been published in the literature that require further study. Many of these questions will
be addressed in this thesis to elucidate how IOP changes relate to the monocular drug
trial.
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Specific Aims
1. To study if first eye response to a medication during the monocular drug trial is
predictive of second eye response if the fellow eye is not used as a control.
2. To study if first eye response to a medication during the monocular drug trial is
predictive of second eye response if the fellow eye is used as a control.
3. To study if the left and right eyes differ in mean IOP.
4. To study if the left and right eyes respond differently to the same medication.
5. To study if correlation between first and second eye response is improved when
controlling for type of glaucoma.
6. To study if correlation between first and second eye response is improved when
controlling for type of medication used in the trial.
7. To study if correlation between first and second eye response is improved when
controlling for prior history of ocular surgery.
8. To study if correlation between first and second eye response is improved when
controlling for race.
9. To study if correlation between first and second eye response is improved when
controlling for use of systemic beta-adrenergic antagonists.
10. To study if certain types of medications when administered monocularly cause a
decrease in IOP in the fellow eye, i.e. the “crossover effect.”
11. To study where the last IOP measurement before therapy is initiated lies on the
diurnal IOP curve.
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Methods
The Human Investigations Committee at the Yale School of Medicine approved
this retrospective, observational study. Medical records of patients seen in the Yale Eye
Center were reviewed by the author to screen for eligibility. In order to be eligible, the
patient had to be: 1) 18 years of age, 2) received diagnosis of glaucoma, 3) had a
monocular trial of a medication followed by binocular therapy (started on a topical
glaucoma medication in one eye, evaluated for response at a later clinic visit, started on
the same medication binocularly, and again evaluated for response at a later visit.)
Exclusion criteria included 1) change of medication or dosage of medication during the
trial, 2) use of a different topical ocular medication in a single eye during the trial, and 3)
use of ocular steroids during the trial.
Data was gathered by the author from medical charts and included demographic
information such as age, race, and gender. Type of glaucoma, presence of other ocular
diseases, history of prior ocular surgery, presence of other systemic diseases, current
medications, and the date of each visit were also collected. IOP data were collected at
each visit during the trial. All measurements were taken during office hours by
experienced practitioners trained to make IOP measurements with a Goldmann
applanation tonometer. IOP readings at 5 visits before the trial were also collected if no
changes in ocular medications occurred during this time. The maximum IOP
measurement was designated as the “peak IOP” and the minimum IOP as the “trough
IOP”.
In 47 patients, the monocular drug trial was evaluated over 3 consecutive visits
(Table 1). In 8 patients, trial was evaluated over 4 consecutive visits. “Baseline IOP” is
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defined as the IOP of each eye at the last measurement before treatment was initiated
(time A for the first eye and time C for the second eye). Response of each eye was
calculated as the change in IOP of each eye from baseline to the next visit (for the first
eye: IOP at time B – IOP at time A; for the second eye: IOP at time D – IOP at time C).
The IOP change of the fellow eye was also calculated for both time periods. Separate
calculation was also performed using the fellow eye as a control for the treated eye. This
was done by subtracting the change in IOP of the fellow eye from the change in IOP of
the treated eye during the same time period.
Table 1 – Order of Visits
For 47 patients
Visit 1
Time A
Visit 2
Time B,
Time C
Visit 3
Time D

Baseline IOP determined, Treatment started in first eye
Response of first eye to medication determined,
Treatment started in second eye.
Response of second eye to medication determined

For 8 patients
Visit 1
Time A
Visit 2
Time B
Visit 3
Time C
Visit 4
Time D

Baseline IOP determined, Treatment started in first eye
Response of first eye to medication determined
Treatment started in the second eye
Response of second eye to medication determined

The left eye and the right eye were compared by examining the baseline IOP and
response to therapy. Analysis of the cross-over effect was performed by looking at the
change in IOP of the non-treated eye. To analyze the presence of regression to the mean,
the IOPs of the previous 5 visits before the trial were compared to the baseline IOP.
Linear regression analysis was performed by the author using the Pearson
correlation coefficient, r, and the coefficient of determination, r2, to look for statistical
correlation between the response of the first eye and second eye to treatment. The paired
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t test was used to look for statistical difference between the IOP of the first eye versus the
second eye and the also for the left eye versus the right eye. Statistical significance was
determined for p values less than 0.05.
Other population subsets were separately analyzed to determine if IOP response
was dependent upon the race of the patient, type of glaucoma, different medications used
in the trial, concurrent use of systemic beta adrenergic antagonists, and history of prior
ocular surgery.
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Results
Fifty-five patients met the eligibility criteria and their charts were reviewed for
this study. Demographic information is included in Table 2. Fifty-five percent of patients
were female, 62% were white, and the mean age was 65. Forty-nine percent of patients
had the diagnosis of glaucoma suspect and 40% had primary open-angle glaucoma.
Prostaglandin analogs (58%) and beta-adrenergic antagonists (20%) were the most
common drugs chosen for the monocular drug trial.
Table 2 – Demographics
Total
Diagnosis
Glaucoma Suspect
Primary Open Angle Glaucoma
Narrow Angle Glaucoma
Traumatic Glaucoma
Normal Tension Glaucoma
Uveitic Glaucoma

55

100%

27
22
2
2
1
1

49.1%
40%
3.6%
3.6%
1.8%
1.8%

Gender
Female
Male

30
25

54.5%
45.5%

Race
White
Black
Hispanic

34
18
3

61.8%
32.7%
5.5%

Mean Age
Median Age

64.7 yrs
67 yrs

(SD = 11.9)

32
11
4
4

58.2%
20%
7.3%
7.3%

2

3.6%

Type of Medication used in Monocular Trial
Prostaglandin analog
Beta-adrenergic antagonist
Alpha 2 agonist
Carbonic anhydrase inhibitor/beta-adrenergic antagonist
combination
Carbonic anhydrase inhibitor

28
Sympathomimetic
Docosanoid

1
1

1.8%
1.8%

Presence of ocular other ocular disease
History of previous eye procedure
Concurrently taking a systemic beta adrenergic antagonist

30
14
13

54.5%
25.5%
23.6%

Left eye was first eye treated in monocular trial
Right eye was first eye treated in monocular trial
SD = standard deviation

30
25

54.5%
45.5%

Are there differences between the right and left eye?
Overall, the baseline IOP of the right eye measured at time A was 21.4 ± 4.8
mmHg (mean ± standard deviation) and the left eye was 22.5 ± 6.8 mmHg (Table 3).
This difference was not found to be statistically significant (p = 0.122). There was
moderate correlation noted between the right and left eye IOPs at baseline (r2 = 0.365).
Table 3 – Intraocular pressures at the baseline reading (time A)
Right Eye
All patients (n = 55)

Left eye

r2

21.4
22.5
0.365
(SD = 4.8)
(SD = 6.8)
Patients with left eye treated
20.9
24.2
0.496
first in trial (n = 30)
(SD = 4.5)
(SD = 7.5)
Patients with right eye treated
21.9
20.5
0.428
first in trial (n = 25)
(SD = 5.3)
(SD = 5.3)
P value for difference was determined from paired student t-test.

P value for
difference
0.122
0.002
0.121

Since the left eye was chosen as the first eye treated in 30 of 55 patients, perhaps
some differences between the eyes would be noted if the population was examined
separately based on which eye was chosen to be treated first. In the 25 patients that had
their right eye chosen as the first treated eye in the monocular drug trial, the average IOP
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of the right eye at baseline was 21.9 ± 5.3 mmHg and the left eye was 20.5 ± 5.3 mmHg,
which was not statistically significant (p = 0.121). In the 30 patients with left eye treated
first, the baseline IOP measured at time A of the right eye was 20.9 ± 4.5 mmHg and 24.2
± 7.5 mmHg in the left eye. There was a statistically significant difference found between
these two values (p = 0.002). Since there was not a consistent pattern noted, the results
when controlling for which eye was treated first are inconclusive.
The IOP responses of the right and left eyes were compared from baseline until
the end of the study to determine if the unequal length of time that one eye was delivered
a medication affected the long-term therapeutic effects of the drug. The right eye
decreased 3.4 ± 5.5 mmHg and left eye decreased 4.4 ± 7.0 mmHg from the beginning to
the end of the trial (Table 4). There was excellent correlation noted in IOP response
between the eye (r = 0.638, p < 0.0001). This indicates that there is excellent symmetry
of therapeutic response of the right and left eye to the same medication over a period of
time. The line of best fit using linear regression analysis to describe the relationship
between left and right eye IOP pairs was ∆IOP

left eye

= 0.8161 (∆IOP

right eye)

- 1.6475

mmHg. The excellent correlation noted above indicates that the IOP data closely fits the
linear regression equation.
Table 4 – Right and left eye over the course of the study
Mean IOP at baseline (time A)
Mean IOP at end of trial (time D)
Change in IOP from time A to time D
Pearson correlation coefficient of change of right
and left eye from time A to time D

Left eye
22.5 (SD = 6.8)
18.1 (SD = 3.9)
-4.4 (SD = 7.0)
r = 0.638

Right eye
21.4 (SD = 4.8)
18.0 (SD = 5.0)
-3.4 (SD = 5.5)
p < 0.0001
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Does the response of the first eye predict response of the second eye?
The eye chosen to be treated first in the monocular drug trial was the eye with the
higher IOP at baseline in 31 of 55 patients. In 9 patients, the eye with lower baseline IOP
was treated first and 15 patients had equal IOPs at baseline. During the monocular phase,
the IOP of the first treated eye decreased 5.8 ± 6.1 mmHg, a reduction of 25%, while the
fellow eye’s IOP increased 0.5 ± 3.5 mmHg, an increase of 2.4% (Table 5). During the
binocular phase, the mean IOP of the second eye decreased 3.4 ± 4.2 mmHg (a 16%
reduction). The mean IOP of the fellow eye (the first eye treated) increased 0.9 ± 4.8
mmHg (a 5.2% increase).
Table 5 – Overall results
Baseline IOP
IOP at assessment (Time B)
Absolute IOP change from Time A to B
Relative change from Time A to B

First eye
23.1 (SD = 6.6)
17.4 (SD = 3.5)
-5.8 (SD = 6.1)
-6.3 (SD = 5.3)

Fellow eye
20.7 (SD = 4.8)
21.2 (SD = 5.2)
0.5 (SD = 3.5)

Baseline IOP (Time C)
IOP at assessment (Time D)
Absolute IOP change from Time C to D
Relative change from Time C to D

Second eye
21.3 (SD = 5.2)
18.0 (SD = 3.8)
-3.4 (SD = 5.7)
-4.2 (SD = 4.5)

Fellow eye
17.3 (SD = 3.4)
18.1 (SD = 5.2)
0.9 (SD = 4.8)

Correlation using absolute changes
R = 0.095
P = 0.49
Correlation using relative changes
R = 0.404
P = 0.002
First eye denotes the eye that the monocular drug trial was performed on.
Second eye denotes the eye that the drug was added to for binocular therapy.
Relative change was calculated using the fellow eye as a control.

There was poor correlation noted between the absolute changes in IOP of the first
eye during monocular therapy and the second eye during binocular therapy when they
were analyzed with the Pearson correlation coefficient (r = 0.095, p = 0.49) (Figure 1).
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This indicates that the first eye is a poor predictor of second eye response when absolute
IOP changes are used. The line of best fit of the absolute IOP change of the first and
second treated eye using linear regression analysis was ∆IOP second eye = 0.09 (∆IOP first eye)
– 2.87 mmHg.
Figure 1
Correlation of Absolute Changes in IOP
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When the fellow eye is not used as a control to adjust for spontaneous changes during the
monocular drug trial, there is poor correlation between the first and second eye response
to the same medication (r = 0.095, p = 0.49). As you can see, the data are widely
scattered around the line of best fit.

When the fellow eye was used as a control for spontaneous diurnal variations, the
relative decrease in IOP of the first treated eye from time A to B was 6.3 ± 5.3 mmHg, a
change of 27.2% (Table 5). When the fellow eye was used as a control for the second eye
from time C to D, the relative reduction in IOP of the second eye was 4.2 ± 4.5 mmHg, a
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decrease of 19.7%. There was statistically significant correlation between the relative
change in IOP in the first eye during monocular therapy and the second eye during
binocular therapy (r = 0.49, p = 0.002) (Figure 2). This indicates that when the fellow eye
is used as a control, the first eye is an excellent predictor of second eye response. The line
of best fit of the relative IOP change of the first and second treated eye using linear
regression analysis was ∆IOP

second eye

= 0.35 (∆IOP

first eye)

– 2.05 mmHg. The excellent

correlation indicates that the IOP data closely fits this line.

Figure 2
Correlation of Relative Changes in IOP
5

IOP change of second treated eye

0

-30

-25

-20

-15

-10

-5

0

5

-5

-10

-15

-20

IOP change of first treated eye

When the fellow eye is used as a control, better correlation is noted between the response
of the first eye treated during the monocular trial and the second eye during binocular
therapy (r = 0.404, p = 0.002). As you can see, there is roughly a linear relationship
between first and second eye response.
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Does the type of medication affect first and second eye correlation?
A subset of 32 patients who were given prostaglandin analogs in the monocular
drug trial were separately analyzed because of the postulated lack of cross-over effect of
this type of medication (Table 6).22 The IOP of the first eye decreased 6.0 ± 6.7 mmHg
while the fellow eye increased 0.6 ± 3.4 mmHg during monocular therapy. During
binocular therapy, the IOP of the second eye decreased 3.6 ± 5.7 mmHg while the fellow
eye increased 1.4 ± 5.4 mmHg. There was not a statistically significant correlation
between the absolute change in IOP of the first eye during monocular therapy and the
second eye during binocular therapy (r = 0.250, p = 0.168). However, statistically
significant correlation was noted when the fellow eye was used as a control (r = 0.400, p
= 0.023).
Table 6 – Medication class

IOP change of first eye (Time A to B)
IOP change of fellow eye (Time A to B)
Relative change of first eye (Time A to B)

Beta-blockers
(n=11)
-7.1 (SD = 5.8)
-0.6 (SD = 3.1)
-6.5 (SD = 7.0)

Prostaglandin
analogs (n=32)
-6.0 (SD = 6.7)
0.6 (SD = 3.4)
-6.6 (SD = 5.4)

IOP change of second eye (Time C to D)
IOP change of fellow eye (Time C to D)
Relative change of second eye (Time C to D)

-3.5 (SD = 4.0)
0.5 (SD = 1.9)
-3.9 (SD = 3.9)

-3.6 (SD = 5.7)
1.4 (SD = 5.4)
-5.1 (SD = 4.9)

Correlation using absolute changes

R = 0.310
P = 0.350
R = 0.538
P = 0.088

R = 0.250
P = 0.168
R = 0.400
P = 0.023

Correlation using relative changes

Since beta-adrenergic antagonists have been found to have a significant crossover
effect, the 11 patients given this type of medication were also analyzed separately.20 The
mean IOP of the first eye decreased 7.1 ± 5.8 mmHg while the fellow eye decreased 0.6 ±
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3.1 mmHg during monocular therapy. During binocular therapy, the mean IOP of the
second eye decreased 3.5 ± 4.0 mmHg while the fellow eye increased 0.5 ± 1.9 mmHg.
There was not a statistically significant correlation when using the absolute IOP change (r
= 0.310, p = 0.350). When using the relative IOP change, there was a trend noted but it
was not statistically significant (r = 0.538, p = 0.088).
To examine if more of a cross-over effect existed in prostaglandin analogs than
beta-blockers, the IOP change in the fellow eye was examined while the first eye was
being treated. There was not a statistically significant difference found in the response of
the fellow eye in these two groups (p = 0.309). This indicates that the statement that a
cross-over effect exists in beta-blockers but not in prostaglandin analogs is not supported
by this study; however as shown above, there was an improvement of correlation of first
and second eye response in prostaglandin analogs than beta-blockers when the fellow eye
was used as a control.

Does type of glaucoma affect first and second eye correlation?
In 22 patients with primary open angle glaucoma, the IOP change of the first eye
was -6.5 ± 7.7 mmHg during monocular therapy and the second eye was -1.5 ± 4.7
mmHg during binocular therapy (Table 7). These were poorly correlated (r = 0.008, p =
0.973). Using relative changes in IOP did not significantly improve correlation (r =
0.199, p = 0.375). In 27 patients with the diagnosis of glaucoma suspect, the IOP change
in the first eye was -5.4 ± 4.4 mmHg during monocular therapy and -4.1 ± 5.2 mmHg of
the second eye during binocular therapy. There was a strong correlation between these
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two values (r = 0.590, p = 0.001). When using relative values, this correlation was even
better (r = 0.629, p = 0.0004).
Table 7 – Type of Glaucoma
POAG (n=22)
IOP change of first eye (Time A to B)
IOP change of fellow eye (Time A to B)
Relative change of first eye (Time A to B)

-6.5 (SD = 7.7)
-0.6 (SD = 3.1)
-5.8 (SD = 6.5)

Glaucoma
Suspect (n=27)
-5.4 (SD = 4.4)
1.1 (SD = 3.1)
-6.6 (SD = 4.7)

IOP change of second eye (Time C to D)
IOP change of fellow eye (Time C to D)
Relative change of second eye (Time C to D)

-1.5 (SD = 4.7)
2.0 (SD = 6.1)
-3.4 (SD = 4.7)

-4.1 (SD = 5.2)
0.4 (SD = 3.2)
-4.6 (SD = 4.0)

Correlation using absolute changes

R = 0.008
P = 0.973
R = 0.199
P = 0.375

R = 0.590
P = 0.001
R = 0.629
P = 0.0004

Correlation using relative changes

Does race affect first and second eye correlation?
Strong correlation was found in 34 White patients when using absolute IOP
changes (r = 0.541, p = 0.001) and when using the relative IOP change (r = 0.599, p =
0.0002) (Table 8). In 21 Black and Hispanic patients, a statistically significant negative
correlation was found using absolute IOP changes (r = -0.513, 0.009). When relative IOP
values were used, poor correlation was found (r = 0.059, p = 0.799).
Table 8 – Race
White (n = 34)
IOP change of first eye (Time A to B)
IOP change of fellow eye (Time A to B)
Relative change of first eye (Time A to B)

-6.5 (SD = 6.1)
0.0 (SD = 3.0)
-6.5 (SD = 5.9)

Black/Hispanic
(n = 21)
-4.7 (SD = 6.1)
1.2 (SD = 4.6)
-5.9 (SD = 4.2)

IOP change of second eye (Time C to D)

-3.7 (SD = 5.2)

-2.9 (SD = 6.5)
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IOP change of fellow eye (Time C to D)
Relative change of second eye (Time C to D)

0.5 (SD = 3.1)
-4.2 (SD = 4.2)

1.4 (SD = 6.7)
-4.3 (SD = 5.0)

Correlation using absolute changes

R = 0.541
P = 0.001
R = 0.599
P = 0.0002

R = -0.513
P = 0.009
R = 0.059
P = 0.799

Correlation using relative changes

Does history of ocular procedure affect first and second eye correlation?
Fourteen patients had undergone an ocular procedure prior to initiation of the
monocular trial (Table 9). These included 2 peripheral iridotomies, 7 laser
photocoagulation procedures, 7 lens removal procedures, and 1 scleral buckle procedure.
In these patients, there was poor correlation between the first eye during monocular
therapy and the second eye during binocular therapy (r = -0.049, p = 0.868). However,
the correlation was statistically significant using relative changes (r = 0.643, p = 0.013).
In 41 patients that had not undergone an ocular procedure, statistically significant
correlation was not found in either absolute changes of IOP (r = 0.180, p = 0.261), or in
relative changes in IOP (r = 0.301, p = 0.056).
Table 9 – History of Surgery
History of ocular
procedure (n=14)
IOP change of first eye (Time A to B)
IOP change of fellow eye (Time A to B)
Relative change of first eye (Time A to B)

-5.0 (SD = 6.2)
1.0 (SD = 5.9)
-6.0 (SD = 5.5)

Patients without
ocular procedure
history (n=41)
-6.1 (SD = 6.1)
0.3 (SD = 2.6)
-6.4 (SD = 5.2)

IOP change of second eye (Time C to D)
IOP change of fellow eye (Time C to D)
Relative change of second eye (Time C to D)

-4.0 (SD = 7.6)
0.6 (SD = 4.0)
-4.6 (SD = 5.6)

-3.2 (SD = 4.9)
0.9 (SD = 5.0)
-4.1 (SD = 4.1)

Correlation using absolute changes

R = -0.049
P = 0.868
R = 0.643
P = 0.013

R = 0.180
P = 0.261
R = 0.301
P = 0.056

Correlation using relative changes
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Does concurrent systemic medication use affect first and second eye correlation?
In order to isolate the effect of systemic medications on IOP, the 13 patients who
were concurrently taking systemic beta-adrenergic antagonists were analyzed
independently (Table 10). There was statistically significant correlation found when
using relative IOP changes (r = 0.598, p = 0.031) but not when using absolute IOP
changes (r= 0.449, p = 0.123). In the 42 patients not on systemic beta-blockers,
statistically significant correlation was observed using relative IOP changes (r = 0.324, p
= 0.036) but not using absolute IOP changes (r = -0.084, p = 0.597). Patients on systemic
beta-blockers did not have a statistically significant difference in absolute IOP response
from those not on systemic beta-blockers during the monocular period (p = 0.0865).

Table 10 – Concurrent systemic beta-adrenergic antagonist use
Concurrent betablocker (n=13)
IOP change of first eye (Time A to B)
IOP change of fellow eye (Time A to B)
Relative change of first eye (Time A to B)

-8.3 (SD = 9.0)
0.0 (SD = 4.5)
-8.3 (SD = 8.3)

Patients not on
beta-blockers
(n = 42)
-5.0 (SD = 4.7)
0.6 (SD = 3.5)
-5.7 (SD = 3.9)

IOP change of second eye (Time C to D)
IOP change of fellow eye (Time C to D)
Relative change of second eye (Time C to D)

-4.2 (SD = 4.9)
0.0 (SD = 1.9)
-4.2 (SD = 4.9)

-3.2 (SD = 5.9)
1.1 (SD = 5.3)
-4.2 (SD = 4.4)

Correlation using absolute changes

R = 0.449
P = 0.123
R = 0.598
P = 0.031

R = -0.084
P = 0.597
R = 0.324
P = 0.036

Correlation using relative changes
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Where does baseline measurement of IOP fall on the diurnal curve?
Ten patients had 5 consecutive visits prior to the initiation of the monocular drug
trial where no changes in medication had taken place (Table 11). In these patients, the
mean IOP of the first treated eye was 23.0 ± 7.9 mmHg. During the baseline visit and the
previous 5 visits, the mean IOP of the first treated eye was 20.6 ± 3.8 mmHg, the average
trough IOP was 17.2 ± 4.0 mmHg, and average peak IOP was 25.0 ± 6.9 mmHg. For the
second eye treated, the mean IOP at time A for these 10 patients was 19.9 ± 4.0 mmHg.
The mean IOP of the second eye at time A and the previous 5 visits was 19.4 ± 3.1
mmHg, the average trough IOP was 15.8 ± 3.8 mmHg, and the average peak IOP was
23.1 ± 2.8 mmHg. For these patients, the baseline IOP at time A was intermediately
between the mean and peak of the diurnal curve for the first treated eye and the baseline
was approximately equal to the mean of the diurnal curve for the fellow eye.
Table 11 – Regression to the Mean
Fellow eye
All eyes
1st treated
eye (n = 10) (n = 10)
(n = 20)
Mean IOP at baseline (time A)
21.5
23.0
19.9
(SD = 6.3)
(SD = 7.9)
(SD = 4.0)
Mean IOP at baseline + 5 previous visits
20.0
20.6
19.4
(SD = 3.4)
(SD = 3.8)
(SD = 3.1)
Mean trough IOP at baseline + 5 previous
16.5
17.2
15.8
visits
(SD = 3.9)
(SD = 4.0)
(SD = 3.8)
Mean peak IOP at baseline + 5 previous
24.0
24.8
23.1
visits
(SD = 5.2)
(SD = 6.9)
(SD = 2.8)
Only included were the 10 patients that had in 5 consecutive visits prior to initiation of
the monocular drug trial did not have any change of medications.
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Discussion
For many years, ophthalmologists have used a monocular trial when starting
glaucoma patients on pharmacotherapy to test the efficacy of the medication. The drug is
started in only one eye so that the fellow eye can be used to control for spontaneous
diurnal variations in intraocular pressure, which was historically assumed to be
approximately equal in both eyes. In this study, we show that when the fellow eye is
used as a control, the first eye is an excellent predictor of response of the second eye.
Also, when the fellow eye is not used as a control, there is sufficient symmetry in IOP
changes in glaucoma suspect patients for the monocular drug trial to be a useful predictor
of IOP response in the fellow eye.

Why does such a difference exist in the correlation when using absolute IOP change and
relative IOP change?
Better correlation between first and second eye response is noted in the overall
patient population as well as many of the subsets when the fellow eye is used as a control
than when absolute intraocular pressures are compared. As has been previously reported,
asymmetric diurnal variations of IOP are substantial and sufficiently skew the data so that
the absolute change in IOP noted in the first eye during the monocular trial does not
predict the absolute change in the second eye during binocular therapy.15
However, even though spontaneous variations are substantial, they can be
mitigated if the fellow eye is used as a control. The better correlation noted with relative
changes indicates that significant symmetry in diurnal variation exists between fellow
eyes to allow an adjustment of the absolute IOP change to be closer to the true
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therapeutic effect. If, however, the diurnal curves between fellow eye pairs were
unrelated, adjustment using the fellow eye would instead confound the data and result in
worse correlation. When examining our data, this is not the case.
Absolute IOP change in one eye does not predict future IOP change in the fellow
eye because of asymmetric spontaneous diurnal variations between two eyes when
comparing different time periods (i.e. the first eye during monocular therapy and the
second eye during binocular therapy). In contrast, good correlation exists when using
relative IOP changes because fellow eyes’ spontaneous variations are symmetrical over
the same time period. Since in the monocular trial, the fellow eye is used as a control
only during the same time period (i.e. the second eye is a control while the first eye is
treated and the first eye is a control while the second is treated), the fellow eye’s diurnal
variation is symmetric enough to allow the other eye to be used as a control.
Realini et al. have shown that when medication is started in both eyes at the same
time, fellow eyes’ absolute IOP changes are well correlated.3 Therefore, therapeutic
response with spontaneous changes over the same time period between fellow eyes are
symmetrical. We supplement these findings by showing that even if a medication is
administered for unequal time lengths in fellow eyes (because only one was used for the
monocular phase of the trial), there is still excellent correlation noted in absolute IOP
change between fellow eyes as long as a sufficient amount of time is allowed to pass for
binocular administration to take effect. Therefore, the major source of variation seen
when comparing the first eye treated in the monocular trial and the second eye during
binocular therapy is due to spontaneous changes in different time periods being
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compared. As a result, one must take the spontaneous changes of the fellow eye over the
same time period into account to obtain meaningful results.

Can we use the fellow eye as a control?
Some researchers have objected to use of the fellow eye as a control stating that
diurnal fluctuations in IOP may be too large in magnitude and independent in each eye
for one eye to serve as a useful predictor of drug efficacy in the fellow eye. In fact,
Realini et al. decided to not use the fellow eye as a control and instead compared only
absolute changes of IOP.15 As we have shown, in order for the monocular trial to be valid
in the general population, one must use the IOP of the fellow eye to predict what the IOP
of the treated eye would have been in the absence of treatment. Only then can a clinician
isolate the therapeutic effect of the medication. If, however, the IOPs independently
fluctuate, then no comparison can be made between fellow eyes and the monocular drug
trial is rendered useless.
Realini et al. also called into question what response constitutes an efficacious
drug.3 They give an example that if the absolute IOPs of both eyes increase after a
monocular trial, but the treated eye increases less than the fellow eye, does that constitute
a successful drug?

Some ophthalmologists may say yes even if the absolute IOP

increased in the treated eye. However, since the overall goal is to lower IOP, this claim is
perplexing. Quite possibly, a single measurement may catch one eye at the IOP peak and
the other eye at the IOP trough giving the clinician a skewed perception. One may make
false conclusions about the extent and asymmetry of glaucomatous damage between the
eyes or about the drug’s efficacy.

42
Thus, there is a critical question of whether one eye can be used as a control for
the fellow eye. The debate can not be settled with a mathematical study, and must
instead be proven with theoretical argument. We counter that even if Realini et al.’s
objection is valid, any skew in comparison of IOP changes between the first and second
treated eye because of asymmetric fluctuations would actually decrease the correlation
observed. If fellow eyes were not the same place on their diurnal pressure curves, this
would serve to scatter the data and would thus, underestimate the correlation. Yet, in
spite of this scattering of data, we still note excellent correlation. Realini et al. state that
intraocular pressures between eyes may be similar on average.15 However, since Pearson
correlation analysis looks for similarities at each data point for each individual and not
for the population as a whole, our data shows there is strong correlation for each
individual (r = 0.404, p = 0.002).
Multiple measurements may allow an ophthalmologist to avert this problem and
get a better picture of the diurnal pressure curve. In fact, ophthalmologists often rely on
IOP measurements over many visits before making a treatment decision unless the IOP is
so high to warrant immediate treatment. However, in a non-emergency setting, research
has not be done to determine if an individual’s IOP curve can be accurately mapped if
measurements are taken across multiple visits or must be during a single day. Since
diurnal pressure curves in the same eye have been shown to shift over time, it is
reasonable to assume the measurements need to be taken preferably over the least amount
of time to reduce the possibility of shifting of the diurnal curve.12

Given the

impracticality for a patient to be in an office setting for 24 hours to check IOP, Zeimer
has advocated for an individual to use a home tonometer multiple times over 24 hours
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and report the readings at a future checkup in order to map the full diurnal pressure
curve.1
If an individual’s diurnal IOP curve can be mapped using multiple measurements,
a monocular trial would cease to be useful. The purpose of using a monocular trial is so
that the response of one eye can be compared to the response in the fellow eye in order to
isolate the effect of spontaneous variations. However, since multiple IOP measurements
would already fully characterize the spontaneous variations, both eyes could now be
started on therapy at the same time. The patient would be instructed to take enough
measurements with a home tonometer both before treatment was started; and then again
when enough time had passed to make a decision about the efficacy of the medication.
The ophthalmologist would then compare the before and after treatment IOP curves to
make a treatment decision.
Using this method, the quandary presented above about what constitutes an
efficacious drug would no longer be in question. Since IOP curves would be directly
compared with each other without any adjustments from the changes observed in the
fellow eye, absolute IOP measurements can now reliably be used. Only if the IOP curve
is noted to be less after treatment will a drug be considered a success and continued. An
ophthalmologist would be able to offer more tailored therapy and perhaps, a different
medication for each eye if the case warrants.

Are there intraocular pressure differences between the left and right eye?
Lee et al. found that asymmetry between the left and right eye to be a sign of
primary open angle glaucoma.23 In order to examine the relationship between the left and
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right eye, we looked at the mean pressures at baseline of the 55 glaucoma patients in our
study. The mean IOP of the left eye was slightly higher than the mean IOP of the right
eye (22.4 mmHg and 21.4 mmHg respectively) although they were not statistically
different. Intraocular pressures in the left and right eye were moderately correlated with
a Pearson correlation coefficient of 0.365. This is similar to previously published studies
including Liu et al. who found a correlation of 0.311 to 0.741 in normal individuals and
Sit et al. who found a correlation of 0.416 to 0.536 in glaucomatous patients.24, 25 Since
the correlation is only moderate, this illustrates that asymmetries exist between eyes
during a single measurement in absence of any effects of medication. Without multiple
measurements mapping each eye’s diurnal curve, we are unable to say whether these
differences reflect asymmetric spontaneous fluctuations (each eye on a different point of
their diurnal curves) or asymmetries of average IOPs (different diurnal curves entirely).
Since the eye with higher IOP at baseline is often the one treated first in the
monocular trial, we looked at if there were differences in the mean IOP between the left
and right eye depending one which one was chosen for treatment. We found that there
was a statistically significant difference in the mean IOP of the left and right eye in
patients when the left eye was the first treated eye; however, no difference was noted
when the right eye was treated first. We believe that these results reflect the subjective
nature of which eye is first chosen for treatment. In fact, Liu et al. found opposite results
in their study, that the average IOP of the right eye than higher than in the left eye.24
Realini et al. found that when medication was added to both eyes at the same
time, the IOP responses of the left and right eyes were correlated.3 However, using linear
regression analysis, they found that the slope of the line of best fit of left and right IOP
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change was 0.77. We compared the IOP at baseline with the IOP after a sufficient
amount of time had passed after initiation of binocular therapy. We, indeed, found that
the left and right eyes were extremely well correlated (p < 0.0001) and the slope of best
fit for our data was 0.81 (Table 4). This suggests that the therapeutic responses of the left
and right eyes are well correlated as long as a sufficient amount of time has passed to
allow the medication to take effect. However, we did expect that the slope of the line of
best fit would be closer to 1 which would indicate an equal response between eyes. IOP
change can be well correlated but not equal if the ratio of IOP change between fellow
eyes is consistent. In both our study and Realini et al.’s study, the right eye response was
less than the left eye response. Perhaps, there are some inherent differences between the
left and right eye. Studies have found various causes for slight asymmetries between IOP
measurements of the left and right eye such as order of measurement and hand and eye
dominance of the patient.28,
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In our study, the IOP of the right eye was regularly

measured first. However, it is unlikely for the order of measurement to cause the larger
decrease noted in the left eye over a period of time.

Is there a cross-over effect?
One of the objections to the monocular trial is that a drug applied in one eye will
decrease the IOP in the fellow eye. This would result in an underestimation of the
therapeutic effect of the treated eye when the fellow is used as a control. To assess this
possibility, we looked at the change in IOP of one eye while the fellow eye is treated with
the medication. In the population as a whole, there doesn’t seem to be a cross-over
effect. In fact, the average IOP of the second eye increases from 20.7 to 21.2 mmHg
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while the first eye is being treated and the first eye increases from 17.3 to 18.1 mmHg
when medication is added to the second eye.
Since beta-adrenergic antagonists are known to cause a cross-over effect, the
subset of patients given this type of medication was examined separately. In the 11
patients given beta-blockers, the fellow eye decreased an average of 0.6 mmHg while the
first eye was being treated. Previous studies have shown a decrease of 1.5 mmHg.20 In
contrast, in patients given prostaglandin analogs where studies have shown there is little
cross over effect, the fellow eye actually increased an average of 0.6 mmHg.22 The
differences in IOP changes observed between patients given prostaglandins and betablockers were not found to be statistically significant. Differences may exist in the types
of medication and be shown in a study with a larger sample size.
The increase in IOP noted in the fellow eye while the other eye is being treated is
perplexing. Perhaps, there are compensatory adjustments to maintain intraocular pressure
in the eye. Local or central mechanisms may serve to balance any reductions in pressure
due to medication. To date, no reports have been published detailing adjustment
mechanisms to maintain a range of normal intraocular pressures.
Since there was less of a cross-over effect in prostaglandin analogs compared with
beta-adrenergic antagonists, one would assume that the correlation noted between first
and second eye responses is better in patients given prostaglandin analogs during the
monocular trial.

This is exactly what we found. The only statistically significant

correlation was found was in patients given prostaglandin analogs when using relative
IOP changes. Perhaps correlation also existed in the group given beta-blockers, however
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it was not found to be statistically significant in part due to the cross-over effect but also
possibly because of the small sample size (n = 11).
Given that topical beta-blockers cross into systemic circulation and decrease IOP
in the contralateral eye, we wondered what effect systemic beta-blocker use would have
on the monocular trial. However, systemic beta-blockade did not affect the results of the
monocular trial. Good correlation was found both in groups using and not using systemic
beta-blockers when the fellow eye was used as a control but not when using absolute IOP
changes. Since systemic medication probably has some influence on IOP, we assumed
that the eye would be less responsive to glaucoma medications in patients given systemic
beta-blockers. In contrast, we found that there was a larger decrease in IOP of the first
eye in patients given systemic beta-blockers (-8.0 mmHg versus -5.0 mmHg), however,
this difference was not found to be statistically significant (p = 0.0865). This may
represent a possible multiplicative effect of the glaucoma medication when used in
conjunction with a systemic beta-adrenergic antagonist or may be because of small
sample size. This needs further investigation.

Is there regression to the mean?
Regression to the mean describes the possibility that at the last measurement
before therapy is initiated, the IOP is more likely to be at the peak of the diurnal curve
than at the average in order to warrant a therapeutic intervention. Since measurement
taken at any other point in time probably has no predilection for a particular point of the
IOP curve, these measurements are more likely to be at the mean IOP. Thus, a selection
bias is introduced that would overestimate the IOP change in the treated eye during the
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monocular trial because not only would therapeutic changes cause a reduction in IOP of
the treated eye, but the eye would also be moving from the peak of its diurnal curve to the
average.
In order to assess this phenomenon, the 5 previous measurements of IOP before
therapy was initiated were compared with the baseline IOP reading. Based on our results,
the average baseline IOP was slightly above the average IOP of the previous 5
measurements. When looking only at the first treated eye, the baseline IOP is closer to
the peak IOP than the mean IOP of the previous 5 measurements. The second treated eye
at baseline was approximately equal to the average of the previous 5 measurements.
However, one can not completely elucidate the entire IOP curve based on measurements
taken at multiple previous visits especially since all were taken during office hours.
More likely, the IOP of the eye chosen for treatment at baseline is somewhere between
the mean and peak of the diurnal curve. Therefore, some regression to the mean
undoubtedly exists; however, this is an inherent source of bias during the monocular trial
and may explain why there is not stronger correlation noted overall. In any case, even
with this confounding bias, there is strong correlation seen when using the fellow eye as a
control as noted above.

Does type of glaucoma affect correlation seen in the monocular trial?
We also looked at the type of glaucoma of the patient to determine if there were
any differences based on the mechanism of the disease. We hypothesized that patients
with primary open angle glaucoma have symmetry of trabecular meshwork impairment
that would result in good correlation of response to medication of the first and second
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eye. However, we found the opposite that almost no correlation existed when using
absolute and relative IOP changes. Realini et al. noted similar findings when using
absolute IOP changes.15
We had interesting results when looking at the glaucoma suspect patients. There
was excellent correlation noted when using absolute IOP changes in the first and second
eye response and even better correlation when using relative IOP changes. This is the
first subset of patients where there was statistically significant correlation noted when
using absolute changes in IOP. This means that in glaucoma suspect patients, the
spontaneous variations between fellow eyes are well correlated and symmetrical over
different periods of time so that the absolute change of IOP of the first eye during the
monocular trial correlates with the absolute change in the second eye during binocular
therapy. Realini et al. did state that they observed better correlation with the non-POAG
patients, yet stated that the correlation was “abysmal” and did not detail their results.15 It
is not known whether they separately analyzed glaucoma suspect patients. The surprising
results in glaucoma suspect patients mean that an ophthalmologist can continue to use the
monocular drug trial to reliably determine the efficacy of a medication even when not
using the fellow eye as a control.
The possible explanation for the large discrepancy of correlation between
glaucoma suspect and POAG patients is multi-faceted. Glaucoma suspect patients are at
the early progressions of disease. Perhaps at this stage, there are not asymmetries in
aqueous inflow or outflow that may occur in advanced cases of disease. Since glaucoma
suspect patients are usually on fewer medications, there is a lower possibility for
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interplay with other ocular medications.

There also may be long-term effects of

medications in POAG patients that permanently alter the response in IOP of each eye.
These results, together with the improvement noted in correlation when the fellow
eye is used as a control, convey that perhaps as the disease become more advanced, the
asymmetry of spontaneous changes in IOP over different time periods increases. In this
case, the fellow eye must be used as a control in POAG patients for the monocular trial to
be valid, but may not be necessary in glaucoma suspect patients. Further studies must be
performed to examine whether symmetry of spontaneous variation is affected by
progression of disease.

Does history of ocular procedure affect first and second eye IOP response?
Patients with previous eye procedures have structural alterations that may affect
the aqueous inflow and outflow. As a result, these patients may not exhibit correlation
between the first and second eye response in the monocular drug trial. However, we
found little difference between past-surgical and non-surgical patient groups. Correlation
was noted in both groups when relative IOP changes were used.

How does race affect the monocular drug trial?
Race is one of the risk factors for the development of glaucoma. Tielsch et al.
found that the prevalence of primary open-angle glaucoma was four to five times higher
in African Americans as Caucasians.36

Our results when controlling for race were

puzzling. The 34 White patients exhibited excellent statistically significant correlation
between first and second eye response both using absolute and relative changes.
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However, the 21 minority patients had a statistically significant negative correlation when
using absolute changes in IOP. This result was highly expected. When the fellow eye
was used as a control, very little correlation was noted.
We are unable to find a satisfactory explanation for these results. The huge
discrepancy when controlling for race points to perhaps a different mechanism of disease
afflicting each population. However, more likely is that there are significant biases in the
patient population used for this study. It is possible that the sample size of the study was
not sufficiently large to allow for correct interpretation of results. Realini et al. did not
control for race in their correlation study.15 Further investigation needs to be performed
to look if there are differences noted in glaucoma based on race. If race is an important
factor, this may shed light on the lack of statistically significant correlation of the first
and second eye IOP response in the general population when using absolute IOP changes.

Limitations
There are limitations to this study that prevent the generalization of results to the
patient population. This was a retrospective, observational study that is subject to the
same confounders of all studies of this kind. It is possible that there was a selection bias
in this study. In majority of patients, the monocular trial was performed on the eye with
the higher IOP. The eye with higher IOP may have been on average close to the peak of
the diurnal curve rather than the mean which would skew the calculated IOP change. In
addition, a single measurement at each time point was used to calculate IOP changes
which, as discussed above, is insufficient for making conclusions about the total diurnal
curve.
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Only patients that had a monocular trial followed by binocular therapy were
included in this study. In clinical practice, a patient may be maintained on monocular
therapy after the drug trial if the IOP of both eyes are deemed to be acceptable. This may
have led to the exclusion of subjects that had asymmetric glaucoma. As a result, better
correlation may have been found that truly occurs in the general glaucoma patient
population.
Patients that had medication changes during the trial were excluded from the
study. This may have excluded patients that had advanced progression of disease or had
co-morbidities requiring therapy. As a result, study may have been skewed towards a
healthier population. We showed that better correlation was noted in glaucoma suspect
patients than in primary open angle glaucoma patients. This selection bias of many
patients with worse progression of disease being excluded may have improved the overall
correlation.

The monocular drug trial is used in clinical practice to isolate the therapeutic
effect of a medication from spontaneous diurnal variations in intra-ocular pressure. Some
have questioned the validity of the trial because of magnitude of the diurnal variations.
Further study is needed to determine if multiple measurements taken over a period of 24
hours can reliably characterize the normal diurnal cycle so that a monocular trial would
no longer be necessary. Until this occurs, we show in this study that the monocular trial is
a useful protocol to determine the efficacy of a medication. When the fellow eye is used
as a control, the first eye response during the monocular drug trial is an excellent
predictor of second eye response. There also may be sufficient symmetry in diurnal
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variations in glaucoma suspect patients for the first eye to be a useful predictor of second
eye response even if the fellow eye is not used as a control.
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